Montreal’s Genizon Biosciences has closed $12.4 million in first tranche secured convertible debenture financing to increase its inventory of GeneMaps and disease drug targets. The syndicated financing includes HBM Bioventures, Biofund Management, and MVI Finance, as well as Genizon management, board members, employees and Illumina Inc
Other stories mentioning these organizations, people and topics
| Organizations: | Biofund Management, Genizon Biosciences, HBM Bioventures, and MVI Finance |
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 1 free article remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.